Oral mucositis: A challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: Diagnosis and management of mucositis

Head and Neck

Volumn 26, Issue 1, 2004, Pages 77-84

  Scully, Crispian ^a   Epstein, Joel ^b   Sonis, Stephen ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Chemotherapy; Mucositis; Oral; Radiotherapy

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BENZYDAMINE; CHLORHEXIDINE GLUCONATE; CISPLATIN; CLOTRIMAZOLE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DISINFECTANT AGENT; DOXEPIN; DOXORUBICIN; DYCLONINE; ETOPOSIDE; FAMCICLOVIR; FLUCONAZOLE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIDOCAINE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NYSTATIN; PENCICLOVIR; PYRROLE DERIVATIVE; SUCRALFATE; UNINDEXED DRUG; VALACICLOVIR; VINBLASTINE;

ANALGESIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CRYOTHERAPY; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RISK; MOUTH HYGIENE; MOUTH MUCOSA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION HAZARD; REMISSION; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT CONTRAINDICATION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CRYOTHERAPY; DIET; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH; MOUTH MUCOSA; ORAL HYGIENE; PAIN; RADIOTHERAPY; STOMATITIS;

EID: 0346102609     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10326     Document Type: Review

References (96)

1. Mead GM. Management of oral mucositis associated with cancer chemotherapy. Lancet 2002;359:815-816.
2. Martin MV, Van Saene HK. The role of oral microorganisms in cancer therapy. Curr Opin Dent 1992;2:81-84.
3. Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 1998;25:538-551.
4. Singh N, Scully C, Joyston-Bechal S. Oral complications of cancer therapies: prevention and management. Clin Oncol (R Coll Radiol) 1996;8:15-24.
5. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998;82:2275-2281.
6. Spijkervet FK, Sonis ST. New frontiers in the management of chemotherapy-induced mucositis. Curr Opin Oncol 1998;10 Suppl 1:S23-S27.
7. Plevova P. Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review. Oral Oncol 1999;35:453-470.
8. Rosenthal C, Karthaus M, Ganser A. New strategies in the treatment and prophylaxis of chemo- and radiotherapy-induced oral mucositis. Antibiot Chemother 2000;50:115-132.
9. Knox JJ, Puodziunas AL, Feld R. Chemotherapy-induced oral mucositis. Prevention and management. Drugs Aging 2000;17:257-267.
10. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000;25:1269-1278.
11. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001;27 Suppl 2:S3-S11.
12. Mueller BA, Millheim ET, Farrington EA, Brusko C, Wiser TH. Mucositis management practices for hospitalized patients: national survey results. J Pain Symptom Manage 1995;10:510-520.
13. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-1617.
14. Kolbinson DA, Schubert MM, Flournoy N, Truelove EL. Early oral changes following bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1988;66:130-138.
15. Toth BB, Martin JW, Fleming TJ. Oral complications associated with cancer therapy. An M. D. Anderson Cancer Center experience. J Clin Periodontol 1990;17:508-515.
16. Jansma J, Vissink A, Bouma J, Vermey A, Panders AK, Gravenmade EJ. A survey of prevention and treatment regimens for oral sequelae resulting from head and neck radiotherapy used in Dutch radiotherapy institutes. Int J Radiat Oncol Biol Phys 1992;24:359-367.
17. Jansma J, Vissink A, Spijkervet FK, et al. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 1992;70:2171-2180.
18. Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999;21:1-11.
19. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 2001;23:389-398.
20. McElroy TH, Guerra ON. Oral/dental management of the head and neck radiation therapy patient. Mo Med 1984;81:15-18.
21. Berkowitz RJ, Strandjord S, Jones P, et al. Stomatologic complications of bone marrow transplantation in a pediatric population. Pediatr Dent 1987;9:105-110.
22. Woo SB, Lee SJ, Schubert MM. Graft-vs.-host disease. Crit Rev Oral Biol Med 1997;8:201-216.
23. Parulekar W, Mackenzie R, Bjarnason G, Jordan RC. Scoring oral mucositis. Oral Oncol 1998;34:63-71.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
25. Kurzrock R, Yap BS, Plager C, et al. Phase II evaluation of PALA in patients with refractory metastatic sarcomas. Am J Clin Oncol. 1984;7:305-307.
26. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 1985;3:326-335.
27. Taylor SG, Davis TE, Falkson G, Keller AM. PALA in advanced breast cancer. A phase II pilot study by the ECOG. Am J Clin Oncol 1982;5:627-629.
28. EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee. Eur J Cancer Clin Oncol 1985;21:1005-1007.
29. Byfield JE, Frankel SS, Hornbeck CL, Sharp TR, Callipari FB, Floyd RA. Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man. Am J Clin Oncol 1985;8:429-440.
30. Becouarn Y, Calabet J, Brunet R. Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas. Tumori 1988;74:75-77.
31. Goodwin JW, Crowley J, Tranum B, et al. Phase II trial of spirogermanium in central nervous system tumors: a Southwest Oncology Group Study. Cancer Treat Rep 1987;71:99-100.
32. Stewart DJ, Perrault DJ, Maroun JA, Lefebvre BM. Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. Am J Clin Oncol 1987;10:335-340.
33. Jabboury K, Holmes FA, Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 1989;64:793-797.
34. Lokich J, Anderson N, Bern M, et al. Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial. Cancer 1991;68:744-746.
35. Saphner T, Tormey DC, Albertini M. Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study. Cancer 1991;68:2359-2362.
36. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8:147-159.
37. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 1992;69:2469-2477.
38. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998;34:39-43.
39. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 1999;85:2103-2113.
40. Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 1994;30B:93-97.
41. Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991;9:449-452.
42. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994;30B:234-236.
43. Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys 1989;16:1571-1575.
44. Kim JH, Chu FC, Lakshmi V, Houde R. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 1986;9:132-134.
45. Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988;3:483-493.
46. Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 1987;114:461-467.
47. Ferretti GA, Raybould TP, Brown AT, et al. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol 1990;69:331-338.
48. Weisdorf DJ, Bostrom B, Raether D, et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989;4:89-95.
49. Wahlin YB. Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 1989;68:279-287.
50. Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1992;73:682-689.
51. Spijkervet FK, Van Saene HK, Panders AK, et al. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol 1989;67:154-161.
52. Samaranayake LP, Robertson AG, MacFarlane TW, et al. The effect of chlorhexidine and benzydamine mouth-washes on mucositis induced by therapeutic irradiation. Clin Radiol 1988;39:291-294.
53. Foote RL, Loprinzi CL, Frank AR, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 1994;12:2630-2633.
54. Ferraro JM, Mattern JQ. Sucralfate suspension for stomatitis. Drug Intell Clin Pharm 1984;18:153.
55. Solomon MA. Oral sucralfate suspension for mucositis. N Engl J Med 1986;315:459-460.
56. Shenep JL, Kalwinsky DK, Hutson PR, et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988;113:758-763.
57. Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol 1990;29:171-173.
58. Barker G, Loftus L, Cuddy P, Barker B. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol 1991;71:288-293.
59. Franzen L, Henriksson R, Littbrand B, Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study. Acta Oncol 1995;34:219-223.
60. Epstein JB, Wong FL. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 1994;28:693-698.
61. Tarnawski A, Hollander D, Gergely H. The mechanism of protective, therapeutic and prophylactic actions of sucralfate. Scand J Gastroenterol Suppl 1987;140:7-13.
62. Garnett WR. Sucralfate-alternative therapy for peptic-ulcer disease. Clin Pharm 1982;1:307-314.
63. Brooks WS, Jr. Sucralfate: nonulcer uses. American College of Gastroenterology Committee on FDA-Related Matters. Am J Gastroenterol 1985;80:206-209.
64. Brown DT, Miller CH, Maupin DE. The effect of sucralfate on the growth of cariogenic streptococci. J Prosthet Dent 1991;66:256-260.
65. Konturek SJ, Brozozowski T, Bielanski W, Warzecha Z, Drozdowicz D. Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats. Am J Med 1989;86:32-37.
66. Allison RR, Vongtama V, Vaughan J, Shin KH. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Invest 1995;13:16-22.
67. Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995;13:2620-2628.
68. Rosso M, Blasi G, Gherlone E, Rosso R. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy. J Chemother 1997;9:382-385.
69. Crawford J, O'Rourke MA. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. Semin Oncol 1994;21:73-78.
70. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-1422.
71. Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-785.
72. Epstein JB, Gorsky M, Epstein MS, Nantel S. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:56-61.
73. Leveque FG, Parzuchowski JB, Farinacci GC, et al. Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy. J Clin Oncol 1992;10:1963-1968.
74. Epstein JB, Gangbar SJ. Oral mucosal lesions in patients undergoing treatment for leukemia. J Oral Med 1987;43:132-137.
75. Bergmann OJ. Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia. Scand J Infect Dis 1991;23:355-366.
76. Bergmann OJ. Oral infections and septicemia in immunocompromised patients with hematologic malignancies. J Clin Microbiol 1988;26:2105-2109.
77. Bergmann OJ. Oral infections and fever in immunocompromised patients with haematologic malignancies. Eur J Clin Microbiol Infect Dis 1989;8:207-213.
78. Dreizen S, McCredie KB, Keating MJ, Bodey GP. Oral infections associated with chemotherapy in adults with acute leukemia. Postgrad Med 1982;71:133-136.
79. Peterson DE, Overholser CD. Increased morbidity associated with oral infection in patients with acute nonlymphocytic leukemia. Oral Surg Oral Med Oral Pathol 1981;51:390-393.
80. Laine PO, Lindqvist JC, Pyrhonen SO, Strand-Pettinen IM, Teerenhovi LM, Meurman JH. Oral infection as a reason for febrile episodes in lymphoma patients receiving cytostatic drugs. Eur J Cancer B Oral Oncol 1992;28B:103-107.
81. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:13-20.
82. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984;53:411-419.
83. Donnelly JP, Dompeling EC, Meis JF, De Pauw BE. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Infect Dis 1995;20:469-470.
84. Nikoskelainen J. Oral infections related to radiation and immunosuppressive therapy. J Clin Periodontol 1990;17:504-507.
85. Heimdahl A, Mattsson T, Dahllof G, Lonnquist B, Ringden O. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1989;68:711-716.
86. Martin MV, Al Tikriti U, Bramley PA. Yeast flora of the mouth and skin during and after irradiation for oral and laryngeal cancer. J Med Microbiol 1981;14:457-467.
87. Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993;76:169-174.
88. Scully C, el Kabir M, Samaranayake LP. Candida and oral candidosis: a review. Crit Rev Oral Biol Med 1994;5:125-157.
89. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. Working party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 1993;32:5-21.
90. Meunier F, Paesmans M, Autier P. Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients. Eur J Cancer B Oral Oncol 1994;30B:196-199.
91. Bodey GP, Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine (Baltimore) 1974;53:209-228.
92. Vries-Hospers HG, Mulder NH, Sleijfer DT, Van Saene HK. The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients. Infection 1982;10:71-75.
93. Scully C, Samaranayake LP. Clinical virology in oral medicine and dentistry. Cambridge: Cambridge University Press; 1992.
94. Schubert MM, Epstein JB, Lloid ME, Cooney E. Oral infections due to cytomegalovirus in immunocompromised patients. J Oral Pathol Med 1993;22:268-273.
95. De Clercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother 1993;32 Suppl A:121-132.
96. Eilers J, Berger AM, Petersen MC. Development, testing, and application of the oral assessment guide. Oncol Nurs Forum 1988;15:325-330.